Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
Adalimumab in Adult Japanese Subjects With Psoriasis
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
- Trial name
- NCT00647400
- Testing
- adalimumab
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- Abbott
Plaque Psoriasis
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07251998
- Testing
- ICP-332 Tablets
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis
Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population
Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16…
- Trial name
- NCT02795416
- Testing
- "Secukinumab" "Cosentyx TM"
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
- Trial name
- Psoriasis (NCT06110676)
- Testing
- LZM012, Secukinumab
- Where
- China
- Volunteers
- 918 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Over 70-year-old Patients with Psoriasis
Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis
Currently, the main systemic drug therapies in China include methotrexate (MTX), cyclosporine A, retinoids, and biologics. In recent years, monoclonal antibody biologics targeting cellular inflammatory factors have been used in…
- Trial name
- NCT06811558
- Testing
- Ixekizumab, Secukizumab
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Moderate to Severe Plaque Psoriasis
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
- Trial name
- NCT00710580
- Testing
- ABT-874, etanercept
- Where
- 42 sites in United States
- Volunteers
- 350 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Plaque Psoriasis
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P55 with Cosentyx in patients with moderate to severe plaque psoriasis
- Trial name
- NCT06630559
- Testing
- CT-P55, EU-approved Cosentyx
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Celltrion
Moderate to Severe Chronic Plaque Psoriasis
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug.
- Trial name
- NCT06591273
- Testing
- Infliximab-dyyb Biosimilar (Remsima)
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
This is a study of a new oral drug used for the treatment of psoriasis. All subjects will get active medication, there is no placebo arm.
- Trial name
- NCT00725348
- Testing
- Talarozole
- Where
- 2 sites in Netherlands
- Volunteers
- 19 people
- Sponsor
- Stiefel, a GSK Company
Psoriasis, Skin Diseases
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT06066125
- Testing
- AK111
- Where
- 34 sites in China
- Volunteers
- 351 people
- Sponsor
- Akeso
Psoriasis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and subjects with moderate to severe psoriasis (PsO).
- Trial name
- NCT01094093
- Testing
- AMG 139
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)
Subjects with moderate-to-severe chronic psoriasis not responding to standard or biologic therapy will be eligible to enroll in this study.
- Trial name
- ESAQUALITY (NCT00687401)
- Testing
- Infliximab
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Acitretin and Etanercept in Psoriasis
To determine whether acitretin plus etanercept is more effective than etanercept alone in clearing psoriasis plaques in adults.
- Trial name
- NCT00156247
- Testing
- acitretin
- Volunteers
- 10 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Chronic Plaque Psoriasis, Obesity
Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
The study hypothesis is to investigate whether a moderate weight loss (i.e. a weight reduction of at least 5%) could improve the response rate to a suboptimal dose of cyclosporine in patients with severe psoriasis.
- Trial name
- NCT00512187
- Testing
- low calorie diet
- Where
- Italy
- Sponsor
- Universita di Verona
Psoriasis
A Study of Mirikizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the…
- Trial name
- NCT03718884
- Testing
- Drug Cocktail, Mirikizumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
- Trial name
- MATURE (NCT03589885)
- Testing
- Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
- Trial name
- BE SHINING (NCT06011733)
- Testing
- Bimekizumab
- Where
- 18 sites in China
- Volunteers
- 133 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis
To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.
- Trial name
- NCT00808223
- Testing
- alefacept
- Where
- 5 sites in United States, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Astellas Pharma Inc
Moderate to Severe Chronic Plaque Psoriasis
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
This is a Phase IIa, randomised, double-blind, placebo-controlled, multiple dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis.The objectives of this study is to investigate…
- Trial name
- AbGn-168H (NCT01855880)
- Testing
- AbGn-168H
- Where
- 15 sites in United States
- Volunteers
- 54 people
- Sponsor
- AbGenomics B.V Taiwan Branch